RARE - Ultragenyx Pharmaceutical Inc.
| Previous Close | 47.31 |
| Open | 46.56 |
| Bid | 44.43 x 1300 |
| Ask | 46.80 x 100 |
| Day's Range | 45.01 - 47.48 |
| 52 Week Range | 41.67 - 90.98 |
| Volume | 38,239 |
| Avg. Volume | 550,829 |
| Market Cap | 2.371B |
| Beta (3Y Monthly) | 4.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.00 |
| Earnings Date | Feb 18, 2019 - Feb 22, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.53 |
Markit•yesterdaySee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- ACCESSWIRE•yesterday
Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
- GlobeNewswire•8 days ago
Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that Crysvita™ (burosumab injection) has been approved by Health Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older. The product is expected to be available for prescription to Canadian patients in early 2019.
- Zacks•9 days ago
Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Markit•20 days agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- Thomson Reuters StreetEvents•23 days ago
Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT
Q3 2018 Ultragenyx Pharmaceutical Inc Earnings Call
- GlobeNewswire•last month
Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
NOVATO, Calif., Nov. 14, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.
Markit•last monthSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•last month
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.
Insider Monkey•last monthAmazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending
Although November 6 is very important to the stock market because it’s election day in the United States, traders are also paying attention to several equities that are trending for various reasons. Without further elaboration, let’s dive in and see why the spotlight is shining on Amazon.com Inc. (NASDAQ:AMZN), The Kraft Heinz Company (NASDAQ:KHC), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), PTC […]
- Zacks•last month
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of 10.31% and 5.01%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Ultragenyx: 3Q Earnings Snapshot
On a per-share basis, the Novato, California-based company said it had a loss of $1.74. The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif., Nov. 05, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.
- Zacks•last month
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
- Zacks•last month
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
- GlobeNewswire•last month
Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, November 5, 2018 at 5pm ET to discuss third quarter 2018 financial results and provide a corporate update. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
- GlobeNewswire•2 months ago
Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced its Phase 3 study of UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) experiencing disabling paroxysmal movement disorders did not achieve its primary endpoint of demonstrating a statistically significant reduction in the frequency of paroxysmal movement events with UX007 treatment compared to placebo, and did not demonstrate a meaningful difference between treatment groups. The study also did not meet its key secondary endpoints.
Markit•2 months agoSee what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
- GlobeNewswire•2 months ago
Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder)
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has exercised its option with REGENXBIO to develop a gene therapy to treat patients with CDD (CDKL5 Deficiency Disorder) utilizing REGENXBIO’s adeno-associated virus (AAV) vectors, including AAV9. CDD is a severe and debilitating neurological disorder that shares many features of Rett Syndrome, though the two disorders are now considered distinct from each other.
- GlobeNewswire•2 months ago
Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII
“The approval of Mepsevii in Brazil is an important milestone, particularly for children with this progressive and debilitating disorder, and also for Ultragenyx because it marks the first regulatory clearance for this important medicine outside of the U.S. and Europe,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. Mepsevii was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the treatment of pediatric and adult patients with MPS VII.
- GlobeNewswire•2 months ago
Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•3 months ago
Ultragenyx Reports Top-line Data From Gene Therapy Candidate
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
- GlobeNewswire•3 months ago
Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline positive safety and efficacy data from the second dose cohort and positive longer-term data from the first dose cohort of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. “Data from the first two dose cohorts continue to demonstrate an acceptable initial safety profile and evidence of clinical activity, with one new patient achieving normalization of ureagenesis in Cohort 2 at 24 weeks,” said Eric Crombez, M.D., Chief Medical Officer of the Ultragenyx Gene Therapy development unit.
